期刊文献+

地氯雷他定治疗慢性特发荨麻疹临床疗效观察 被引量:3

Observe the Clinical Curative Effect of Treating CIU by Desloratadin
下载PDF
导出
摘要 目的:为了观察地氯雷他定治疗慢性特发性荨麻疹的临床疗效。方法:自身对照方法,用地氯雷他定对慢性特发性荨麻疹治疗前后进行临床对比观察。共观察96例,治疗后1、2、4周观察并记录患者瘙痒程度、风团数量以及风团大小,按4级评分法计分。结果:总积分治疗前为(8.37±0.45),治疗后1、2、4周分别下降为(4.38±0.76)、(2.74±0.65)、(0.31±0.53),与治疗前比较差异有统计学意义(P<0.01),治疗1、2、4周总缓解率分别为59.4%、78.1%、89.6%,三者比较存在显著性差异(X^2=36.47,P<0.01)。结论:地氯雷他定治疗慢性特发性荨麻疹有显著疗效,并且随治疗时间的延长其总缓解率有明显增加,值得临床应用。 Objective:To observe the clinical curative effect of treating CIU by desloratadin, the author adopt the way of self- comparison. Methods: Observing the clinical comparison of treating CIU before and after taking desloratadin, there are totally 96 exampies. After one week, two weeks and four weeks, file author records the degree of itch, the quantities of wheal, the big or small of wheal, and keep the scores by 4 -degree standards of grading. Results: The total score was (8. 37 ± 0. 45 ) before treating and (4.38 ± 0. 76 ) one week later, ( 2.74 ± 0. 65 ) two weeks later and (0. 31 ± 0. 53 ) four weeks later. The differenees are of statistical meaning ( P 〈 0. 01 ). The lysis rates affer treating one week, two weeks and four weeks are separately 59. 4% ,78.1% and 89.6%. There exist remarkable differences(x^2 = 36.47, P 〈 0. 01 ). Conclusion: Desloratadin had the notable curative effect on CIU. With the extension of the treatment time,the lysis rate increase obviously. Desloratadin is worthy of clinical practice.
作者 陈泳
出处 《中国医药导刊》 2008年第3期411-412,共2页 Chinese Journal of Medicinal Guide
关键词 荨麻疹 特发性 慢性 地氯雷他定 临床疗效观察 Urticaria Idiopathic Chronic Desloratadin Clinical efficacy
  • 相关文献

参考文献7

二级参考文献30

  • 1[1]Henz. The pharmacologic profile of desloratadine:a review[J]. Allergy,2001,56(1) :7- 13.
  • 2[2]Anthes J, Richard C, West RE, et al. Functional characterization of desloratadine and other antihistamines in human H1receptors[ J ]. Allergy, 2000,55 (Supple63): S279.
  • 3[3]Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine,a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, andantiallergic effects[J]. Arzneimittelforschung, 2000,50(2): 345 - 352.
  • 4[4]Kreutner W, Hey JA, Anthes J, et al. Preclinical studies of desloratadine, a non-sedating, selective histamine H1 receptor antagonist with antiallergic activity[J ]. Allergy, 2000,55 (Supple63): 278.
  • 5[5]Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symtoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study[J ]. Int J Dermatol, 2001,40 ( 1 ): 72- 76.
  • 6[6]Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine[J] .J Allergy Clin Immunol,2001,107(4) :751 - 762.
  • 7[7]McClellan K, Jarvis B. Desloratadine [J ]. Drugs, 2001,61 (6): 789 -796.
  • 8[8]Barechi ME, Casciano CN, Johnson WW, et al. In vitro characterization of the inhibition profile of loratadine[ J ]. Drug Metab Dispos, 2001,29(9): 1173 - 1175.
  • 9[1]Henz.The phannacologic profile of desloraLadine:a review[J].Allergy,2001,56(1):7-13.
  • 10[2]Barechi ME,Casciano CN,John WW,el al Lnvitro characterization of the inhibition profile of loratadinc[J]Drug Metab Dispos,2001,29(9):1173-1175.

共引文献109

同被引文献13

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部